drugset / Trial / NCT00774553

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

NCT00774553

Phase 1 Completed 70 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess safety and tolerablility of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes on top of metformin.

Timeline

Start
2008-10
Primary completion
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule Oral